Thursday, June 30, 2011
The National Parkinson Foundation (NPF) has awarded more than $1 million for clinical research projects. Through NPF’s individual investigators awards program, it is supporting work to advance three key areas of Parkinson’s disease: an advanced biomarker study, a clinical trial to treat memory impairment and a study of the effectiveness of a treatment for sleep apnea.
Sorbent Therapeutics, a biopharmaceutical company, has expanded its Series B financing from September 2010 by $36 million. This brings the total proceeds of the second financing round to $53 million. Investor Novartis Venture Funds led the financing, joining existing investors Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem.
Omeros said it has identified compounds that interact with orphan G protein-coupled receptors (GPCRs) P2Y8 and OPN4. P2Y8 (also known as P2RY8) is associated with acute lymphoblastic leukemia (ALL), an aggressive cancer of the white blood cells and the most common type of malignancy diagnosed in children.